Frontage Laboratories Expands Early-Phase Clinical Capabilities to Support Global Drug Development
Saturday, January 31, 2026
Frontage Laboratories has expanded its early-phase clinical research capabilities in the United States and China to better support global drug development. The move strengthens the company’s ability to deliver faster and high-quality clinical solutions for pharmaceutical and biotechnology companies.
In the US, Frontage operates a 160-bed Phase I clinical unit in Secaucus, New Jersey. The site supports large Phase I and bioequivalence studies, as well as radiolabelled human AME research. The company has also enhanced its C14-hAME services with a specialised unit and an onsite nuclear pharmacy, in line with updated FDA guidance.
To meet rising demand, Frontage is extending its work into oncology Phase I trials through partnerships with hospitals and clinical networks. The company is also well placed to manage high-volume bioequivalence programmes linked to upcoming patent expiries. Coordination with Frontage China supports flexible multi-regional clinical trials.
All services are delivered through Frontage’s integrated “one-stop shop” model, covering clinical research, bioanalysis, DMPK and manufacturing, to reduce timelines and overall study costs.
Source: globenewswire.com
